<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099591</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00016</org_study_id>
    <secondary_id>UTN: U1111-1154-5575</secondary_id>
    <secondary_id>2013-003935-32</secondary_id>
    <nct_id>NCT02099591</nct_id>
  </id_info>
  <brief_title>Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients</brief_title>
  <official_title>A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages â‰¥ 6 Months to &lt; 18 Years Receiving Treatment With Opioids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Pharmaceutical Development Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through
      population PK in paediatric patients with opioid induced constipation (OIC) or at risk of
      OIC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterise the pharmacokinetics of naloxegol after single oral dose and through population pharmacokinetics in paediatric patients with opioid induced constipation</measure>
    <time_frame>Day 1 : Pre-dose (within 30 min prior to drug dosing), 0.5, 1, 2, 4, 6, 8, 10 and 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics of naloxegol after multiple, once-daily, oral dosing in paediatric opioid induced constipation patients who continue participation beyond Day 1</measure>
    <time_frame>Day 7 (minimum 3 days of naloxegol treatment): pre-dose and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability of naloxegol liquid drug formulation</measure>
    <time_frame>Day 1 and Day 2 after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of the patient to swallow the tablet</measure>
    <time_frame>Day 1 and Day 2 after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome measures by assessment of laxative use</measure>
    <time_frame>From Day 1 until the End of treatment (26 week of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Constipation, Signs and Symptoms, Digestive</condition>
  <arm_group>
    <arm_group_label>Age group: &gt; = 12y to &lt; 18y - Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group: &gt; = 12y to &lt; 18y - Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group: &gt; = 6y to &lt; 12y - Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group: &gt; = 6y to &lt; 12y - Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group: &gt; = 6mo to &lt; 6y - Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group: &gt; = 6mo to &lt; 6y - Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol</intervention_name>
    <description>Opioid Antagonist</description>
    <arm_group_label>Age group: &gt; = 12y to &lt; 18y - Higher dose</arm_group_label>
    <arm_group_label>Age group: &gt; = 12y to &lt; 18y - Lower dose</arm_group_label>
    <arm_group_label>Age group: &gt; = 6mo to &lt; 6y - Higher dose</arm_group_label>
    <arm_group_label>Age group: &gt; = 6mo to &lt; 6y - Lower dose</arm_group_label>
    <arm_group_label>Age group: &gt; = 6y to &lt; 12y - Higher dose</arm_group_label>
    <arm_group_label>Age group: &gt; = 6y to &lt; 12y - Lower dose</arm_group_label>
    <other_name>Moventig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria, patient with:

          -  malignant or non-malignant pain who are receiving or (are about to receive) acute or
             chronic treatment with opioids

          -  newly diagnosed constatipation, with history of constipation treated with laxatives or
             expected to develop constipation after opioid treatment

          -  ability to be present in the clinic for at least 10 hours following the first study
             drug for blood sampling and to return at 24 hours for blood sampling.

        Main exclusion criteria:

          -  Current acute or chronic use of methadone

          -  History of an neoplasm or an ongoing gastrointestinal-related issue

          -  Signs or symptoms of gastrointestinal obstruction

          -  History of prolonged neutropenia or thrombocytopenia with clinical sequelae.

          -  Patients currently receiving the first cycle of chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center, Oncology Institute</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital - Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Oncology Unit Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de HematologÃ­a y OncologÃ­a PediÃ¡trica - Hospital Universitario HM Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>03191</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hosptial NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Children's Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Constipation</keyword>
  <keyword>Colonic Inertia</keyword>
  <keyword>Dyschezia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Naloxegol</keyword>
  <keyword>Paediatric</keyword>
  <keyword>Opioids</keyword>
  <keyword>Opioid induced constipation</keyword>
  <keyword>OIC</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

